
TRAX Stock Forecast & Price Target
TRAX Analyst Ratings
Bulls say
First Tracks is well-positioned in the market with their clinical-stage pipeline, especially with the potential expansion into the dermatology market. With positive results in their Phase 2b trial for RA and ongoing studies for ANB033 in celiac disease and EoE, the company has the potential for significant growth and a potential market value of $5.4 billion. The company also has strong financials, including FDA Fast Track Designation and positive earnings, indicating a strong outlook for investors.
Bears say
First Tracks is a clinical-stage biotech company with a focus on delivering immunology therapeutics for autoimmune and inflammatory diseases. However, the company faces several challenges, including intense competition in the EoE space and a delayed timeline for the launch of its lead candidate ANB101. Additionally, there are potential risks to the attainment of its estimated valuation and approval for its pipeline products if efficacy or safety issues arise. As a result, it is important for investors to closely monitor the company's progress and risks before considering an investment in First Tracks' stock.
This aggregate rating is based on analysts' research of First Tracks Biotherapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
TRAX Analyst Forecast & Price Prediction
Start investing in TRAX
Order type
Buy in
Order amount
Est. shares
0 shares